Cargando…

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells

One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7. We have previously reported that Phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarwar, Martuza, Semenas, Julius, Miftakhova, Regina, Simoulis, Athanasios, Robinson, Brian, Wingren, Anette Gjörloff, Mongan, Nigel P., Heery, David M., Johnsson, Heather, Abrahamsson, Per-Anders, Dizeyi, Nishtman, Luo, Jun, Persson, Jenny L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325347/ https://www.ncbi.nlm.nih.gov/pubmed/27588408 http://dx.doi.org/10.18632/oncotarget.11757

Ejemplares similares

The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer
por: Larsson, Per, et al.
Publicado: (2019)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer
por: Larsson, Per Flodbring, et al.
Publicado: (2022)

Establishment of Prostate Tumor Growth and Metastasis Is Supported by Bone Marrow Cells and Is Mediated by PIP5K1α Lipid Kinase
por: Karlsson, Richard, et al.
Publicado: (2020)

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer
por: Wang, Tianyan, et al.
Publicado: (2022)

Different expression levels of glycans on leukemic cells—a novel screening method with molecularly imprinted polymers (MIP) targeting sialic acid
por: El-Schich, Zahra, et al.
Publicado: (2016)

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
por: Mandel, Anna, et al.
Publicado: (2018)

K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer
por: Johnson, Heather, et al.
Publicado: (2022)

Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients
por: Johnson, Heather, et al.
Publicado: (2022)

The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor
por: Sarwar, Martuza, et al.
Publicado: (2018)

Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration‐resistant prostate cancer
por: Semenas, Julius, et al.
Publicado: (2020)

Overcoming Drug Resistance and Treating Advanced Prostate Cancer
por: Semenas, Julius, et al.
Publicado: (2012)

Digital Holographic Microscopy for Non-Invasive Monitoring of Cell Cycle Arrest in L929 Cells
por: Falck Miniotis, Maria, et al.
Publicado: (2014)

Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
por: Johnson, Heather, et al.
Publicado: (2020)

A 23‐Gene Classifier urine test for prostate cancer prognosis
por: Guo, Jinan, et al.
Publicado: (2021)

Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
por: Guo, Jinan, et al.
Publicado: (2021)

Interfacing antibody-based microarrays and digital holography enables label-free detection for loss of cell volume
por: El-Schich, Zahra, et al.
Publicado: (2015)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Recent Advances in Molecularly Imprinted Polymers and Their Disease-Related Applications
por: Cabaleiro-Lago, Celia, et al.
Publicado: (2023)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

In vitro effects of undifferentiated callus extracts from Plantago major L, Rhodiola rosea L and Silybum marianum L in normal and malignant human skin cells
por: Gjörloff Wingren, Anette, et al.
Publicado: (2023)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Cyclin A1 Modulates the Expression of Vascular Endothelial Growth Factor and Promotes Hormone-Dependent Growth and Angiogenesis of Breast Cancer
por: Syed Khaja, Azharuddin Sajid, et al.
Publicado: (2013)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions
por: Gobbo, Marina G., et al.
Publicado: (2015)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

An Epitope‐Imprinted Biointerface with Dynamic Bioactivity for Modulating Cell–Biomaterial Interactions
por: Pan, Guoqing, et al.
Publicado: (2017)

Fysikkens år - 2005
por: Johnsson, Anders
Publicado: (2004)

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
por: Thaper, Daksh, et al.
Publicado: (2018)

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells
por: Han, Yangyang, et al.
Publicado: (2017)

Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis
por: Wegiel, Barbara, et al.
Publicado: (2008)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_02iq6hj8sqbt9gk5uvnoot0sdm